N-Formylated humanin activates both formyl peptide receptor-like 1 and 2.
Harada. Masataka M; Habata. Yugo Y; Hosoya. Masaki M; Nishi. Kazunori K; Fujii. Ryo R; Kobayashi. Makoto M; Hinuma. Shuji S
Key Findings
- Humanin directly binds to FPRL1 and FPRL2 receptors
- N‑formylated humanin is ~300‑times more potent than regular humanin in activating FPRL1
- Both forms trigger cell movement (chemotaxis) and suppress cAMP signaling in the test cells
Practical Outcomes
- Right now there’s no clear way to use this information for supplements or protocols. It suggests that making a formyl‑modified humanin could be a more powerful neuroprotective agent, so future research may focus on such analogs for longevity or brain health.
Summary
Scientists found that the small protein humanin can stick to two cell‑surface receptors called FPRL1 and FPRL2, and that a slightly modified version (adding a formyl group) works far better. This helps explain how humanin protects brain cells, but the study was done in engineered hamster cells, not people, and it doesn’t give dosing advice.
Abstract
We have discovered that humanin (HN) acts as a ligand for formyl peptide receptor-like 1 (FPRL1) and 2 (FPRL2). This discovery was based on our finding that HN suppressed forskolin-induced cAMP production in Chinese hamster ovary (CHO) cells expressing human FPRL1 (CHO-hFPRL1) or human FPRL2 (CHO-hFPRL2). In addition, we found that N-formylated HN (fHN) performed more potently as a ligand for FPRL1 than HN: in CHO-hFPRL1 cells, the effective concentration for the half-maximal response (EC(50)) value of HN was 3.5nM, while that of fHN was 0.012nM. We demonstrated by binding experiments using [(125)I]-W peptide that HN and fHN directly interacted with hFPRL1 on the membrane. In addition, we found that HN and fHN showed strong chemotactic activity for CHO-hFPRL1 and CHO-hFPRL2 cells. HN is known to have a protective effect against neuronal cell death. Our findings contribute to the understanding of the mechanism behind HN's function.
Study Information
pubmed
2004
2004-11-05T00:00:00.000Z
10.1016/j.bbrc.2004.09.046